




RealRate

PHARMACEUTICAL 2015

Immune Pharmaceuticals INC
Rank 194 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Immune Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Immune Pharmaceuticals INC is the variable Assets, Current, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 189%, being 65% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	6,887
Cost of Goods Sold	0
Intangible Assets	3,415
Liabilities, Current	7,417
Liabilities, Non-Current	0
Other Assets	27,521
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	12,903
Other Net Income	-7,187
Other Revenues	2.0
Property and Equipment	41
Research and Development	5,640
Selling, General and Administrative Expense	10,725

Output Variable	Value in 1000 USD
Assets	37,864
Liabilities	20,320
Expenses	16,365
Revenues	2.0
Stockholders Equity	17,544
Net Income	-23,550
Comprehensive Net Income	-23,550
BaseVar	40,869
ECR before LimitedLiability	51%
Economic Capital Ratio	189%